Enjoy reading your contributions synaphai and respect your opinions as such.
How does Anteris compete with market leaders as per Edwardes LS, spend of 1 billion US dollars on R& D alone, on commercialisation will this IP be disruptive or on par with its earlier IP Cardiocel in commercial success.
Actual costings for commercialisation?, it seemly will see further dilution on levels that have gone on up to date, 4 years more till successful commercialisation BASED ON WHAT LEVEL OF FUNDING, would like to see a figure for that.
WPs ‘very unique to influence people …’, 100%, the CRs, last two at $23/$16, that was certainly a good ‘sell’. Cannot believe that analyst actually based her piece on what Wayne told her!
Way too much ‘bullshitting’ and not having delivered as had its cost, this stock had its ‘honeymoon’ period, at $170 plus, that honeymoon period well and truly over now.
Will view with interest the progress of this Company, the upcoming IPO listing details, and the quarterly reports to come.
All the best mate, cheers.
Imho, not advice.
AVR Price at posting:
$8.80 Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)